TYK-nuHomo sapiens (Human)Cancer cell line
Also known as: TYKNU, TYKnu, TYK-NU
Quick Overview
Human ovarian cancer cell line for research on molecular mechanisms and drug development.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1776 |
|---|---|
| Species | Homo sapiens (Human) |
Donor Information
| Age | 38 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | asian |
Disease Information
| Disease | High grade ovarian serous adenocarcinoma |
|---|---|
| Lineage | Ovary/Fallopian Tube |
| Subtype | High-Grade Serous Ovarian Cancer |
| OncoTree Code | HGSOC |
DepMap Information
| Source Type | HSRRB |
|---|---|
| Source ID | ACH-000430_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg175His (c.524G>A) | Unspecified | Somatic mutation acquired during proliferation | from parent cell line YCC-3 |
| MutationSimple | NRAS | p.Gln61Lys (c.181C>A) | Unspecified | Acquired during resistance selection process | PubMed=26214590 |
| MutationSimple | NRAS | p.Gly12Asp (c.35G>A) | Unspecified | Somatic | Wistar |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Velculescu V.E., Scharpf R.B.
Cell Rep. 25:2617-2633(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Nat. Commun. 7:12645.1-12645.14(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.
Int. J. Oncol. 46:2389-2398(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Evaluating cell lines as tumour models by comparison of genomic profiles.
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Nat. Commun. 4:2126.1-2126.10(2013).
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Lessey B.A., Jordan V.C., Bradford A.P.
Gynecol. Oncol. 127:241-248(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Takayama M., Sato A., Inazawa J.
Jpn. J. Cancer Res. 93:1114-1122(2002).
A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization.
Sato A., Inazawa J.
Gynecol. Oncol. 81:172-177(2001).
Screening the p53 status of human cell lines using a yeast functional assay.
Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Mol. Carcinog. 19:243-253(1997).
Establishment of a cell line from human ovarian cancer (undifferentiated carcinoma of FIGO classification) and analysis of its cell-biological characteristics and sensitivity to anticancer drugs.
Yoshiya N.
Nihon Sanka Fujinka Gakkai Zasshi 38:1747-1753(1986).